Trials / Completed
CompletedNCT01697501
A Study Evaluating IL28B Polymorphism in Patients With HBeAg-Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML18253
Cross-sectional Multicenter Study Evaluating the IL28B Polymorphism in Patients With HBeAg-negative Chronic Hepatitis B Treated With Pegylated Interferon Alfa-2a in the Course of Peg.Be.Liver Study
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 88 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This cross-sectional multicenter study will evaluate the IL28B polymorphism in patients with HBeAg-negative chronic hepatitis B treated with Pegasys (peginterferon alfa-2a) in the predecessor ML18253 study. The study consists of a single visit where eligible patients will undergo a blood test for IL28B genotyping, with a phone follow-up 7 days after the visit.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Interleukin 28B testing | Blood sampling for IL28B genotyping |
Timeline
- Start date
- 2012-11-08
- Primary completion
- 2013-06-21
- Completion
- 2013-06-21
- First posted
- 2012-10-02
- Last updated
- 2017-04-10
- Results posted
- 2015-07-10
Locations
12 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT01697501. Inclusion in this directory is not an endorsement.